PICATO (ingenol mebutate) 0.015%, 0.05% gel by LEO Pharma The Food and Drug Administration (FDA) is warning about reports of severe allergic reactions and herpes zoster associated with the use of ...
The US Food and Drug Administration (FDA) has received reports of severe allergic reactions and herpes zoster in patients with actinic keratosis treated with ingenol mebutate (Picato, LEO Pharma) gel, ...
As a precaution, the European Medicines Agency (EMA) has recommended that patients stop using ingenol mebutate (Picato) while the agency continues to review the safety of the topical treatment, which ...
A new treatment for skin damage that can lead to cancer has been created from the sap of a common garden weed. Picato gel is a fast-acting treatment for actinic keratosis (AK), which appears as red, ...
Issue: Use of the drug Picato may increase the risk of skin cancer. What to do: Look for any new scaly red patches, open sores, elevated or warty growths where the medication is applied. If you find ...
The European Medicines Agency’s safety committee (PRAC) has confirmed that LEO’s Laboratories’ Picato (ingenol mebutate), used to treat the skin condition actinic keratosis, may increase the risk of ...
PICATO (ingenol mebutate) 0.015%, 0.05% gel by LEO Pharma LEO Pharma announced that the FDA has approved Picato (ingenol mebutate gel) for the topical treatment of actinic keratosis. LEO Pharma ...
Last September, the EMA's Pharmacovigilance Risk Assessment Committee announced a review of data on skin cancer in patients using the drug. LEO Pharma has recalled all unexpired stock of Picato ...
EMA has started a data review of Picato (ingenol mebutate) to investigate the potential for skin cancer risk. The European Medicines Agency (EMA) announced on Sept. 6, 2019 that it was initiating a ...
Issue: Using Picato may increase the risk of non-melanoma skin cancer. What to do: Stop your treatment and talk to your healthcare professional about other treatment options. Monitor your skin for ...
Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato(R) (ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results